Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery), By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Amyloidosis Treatment Market Size & Share Analysis

The global amyloidosis treatment market size was valued at USD 5.99 billion in 2025 and is projected to grow from USD 6.42 billion in 2026 to USD 11.23 billion by 2034, registering a CAGR of 7.23% during the forecast period (2026-2034). North America dominated the amyloidosis treatment market with a share of 39.42% in 2025.

Amyloidosis treatment involves therapies designed to reduce the production or accumulation of abnormal amyloid fibrids that deposit in tissues and organs, disrupting their normal function. Amyloidosis treatments are commonly classified under HSN Code 3004 (medicaments for therapeutic or prophylactic uses, put up in measured doses or retail packaging) and SIC Code 2834 (Pharmaceutical Preparations).

The amyloidosis treatment market demand is driven by improved disease recognition, advances in diagnostic methods, and the development of therapies targeting specific amyloid-producing mechanisms. Healthcare providers use gene silencing therapies and monoclonal antibodies to control abnormal protein production, contributing to amyloidosis treatment market growth.

Amyloidosis Treatment Market Segmentation Analysis

By Treatment

Chemotherapy led the treatment segment with a share of 34.6%, supported by its use in treating certain forms of amyloidosis, particularly light-chain (AL) amyloidosis, where therapy targets the abnormal plasma cells producing amyloid-forming proteins.

Supportive care is projected to register a CAGR of 8.26% during the forecast period, fueled by the need to manage organ complications and maintain quality of life in patients with amyloidosis. Measures such as managing fluid retention, addressing cardiac symptoms, and supporting kidney function complement disease-directed treatment and ongoing clinical monitoring.

Request Customizationto receive a tailored report.

By End Use

Hospitals and clinics accounted for a 67.4% share of the end-user segment, reflecting their role in diagnosing amyloidosis and monitoring complications affecting the heart, kidneys, and other organs. Access to multidisciplinary specialists and advanced diagnostic services supports the management of complex cases.

The home care settings segment is estimated to witness a CAGR of 8.72% during the forecast period, driven by the demand for ongoing symptom management and follow-up care outside hospital facilities.

Speak to an Analystto discuss market opportunities.

Amyloidosis Treatment Market Regional Outlook

North America Amyloidosis Treatment Market

The North America amyloidosis treatment market accounted for a dominant share of 39.42% in 2025.

U.S. Amyloidosis Treatment Market

U.S. market benefits by the FDA’s traditional approval of daratumumab and hyaluronidase in combination with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain (AL) amyloidosis. The decision was based on clinical trial results showing improvements in major organ deterioration, progression-free survival, and overall survival compared with the treatment regimen without daratumumab.

Canada Amyloidosis Treatment Market

Canada’s market is supported by the availability of specialized assessment and treatment pathways for cardiac amyloidosis, including transthyretin amyloid cardiomyopathy (ATTR-CM). Health Canada has approved vutrisiran for adults with wild-type or hereditary ATTR amyloidosis with cardiomyopathy. These developments highlight the role of disease-specific therapies, cardiac assessment, and ongoing monitoring in amyloidosis care.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Amyloidosis Treatment Market

The Asia Pacific amyloidosis treatment market is expected to achieve a growth rate of 9.11% during the forecast period, making it the fastest-growing region.

China Amyloidosis Treatment Market

China's First List of Rare Diseases, published by the National Health Commission and other government departments, includes hereditary transthyretin amyloidosis. This supports greater recognition of the condition within the healthcare system, leading to treatment focus across healthcare systems.

Japan Amyloidosis Treatment Market

Designated Intractable Disease program in Japan includes systemic amyloidosis and provides eligible patients with access to financial assistance for qualifying medical expenses. This framework helps address the long-term treatment burden associated with amyloidosis and supports the need for specialized care. 

India Amyloidosis Treatment Market

Ministry of Health and Family Welfare also highlighted early diagnosis, innovation, and stronger collaboration as priorities for rare-disease management, reinforcing the importance of improving specialist diagnostic and treatment pathways. For instance, The Amrita Amyloid Centre in Kochi brings together specialists across these disciplines and offers advanced diagnostic capabilities, including cardiac imaging, tissue biopsy, mass spectrometry-based amyloid typing, and genetic testing for transthyretin variants

Europe Amyloidosis Treatment Market

The Europe amyloidosis treatment market is anticipated to record a growth rate of 6.74% during the forecast period.

United Kingdom Amyloidosis Treatment Market

National Amyloidosis Centre in London offers a specialized service that provides assessment, treatment, and follow-up for patients with amyloidosis and related disorders. The UK’s National Institute for Health and Care Excellence (NICE) also provides guidance on specialized treatments such as patisiran for hereditary transthyretin amyloidosis.

Germany Amyloidosis Treatment Market

Amyloidosis Center at Heidelberg University Hospital brings together specialists in hematology, cardiology, nephrology, and neurology to diagnose and treat different forms of amyloidosis. The center provides individualized treatment plans, including chemotherapy and stem cell transplantation for light chain amyloidosis, along with therapies for other disease types.

Latin America Amyloidosis Treatment Market

Latin American amyloidosis treatment market is estimated to grow at a CAGR of 7.41% during the forecast period. Brazil’s Ministry of Health’s Clinical Protocol and Therapeutic Guidelines for Transthyretin Amyloidosis establishes criteria for diagnosis, treatment, patient eligibility, and follow-up through the public healthcare system. Mexican Position Statement for the Diagnosis and Treatment of Cardiac Amyloidosis also provides a diagnostic algorithm combining cardiac imaging and laboratory tests. It emphasizes early recognition of warning signs and individualized treatment based on disease subtype and comorbidities.

Middle East & Africa Amyloidosis Treatment Market

The Middle East & Africa amyloidosis treatment market is projected to grow at a CAGR of 7.16% during the forecast period. UAE's Cleveland Clinic Abu Dhabi, which operates a dedicated Multiple Myeloma and Amyloidosis Program. The program brings together hematologists, cardiologists, nephrologists, and other specialists to diagnose and manage amyloidosis and related plasma cell disorders. The Amyloidosis Africa initiative, which includes South African cardiology expertise, promotes clinician training, awareness, and improved diagnostic pathways for cardiac amyloidosis across the continent.

Competitive Landscape

The amyloidosis treatment market competitive landscape is highly fragmented, with established pharmaceutical companies, biotechnology firms, and specialized developers of therapies for rare diseases. Key players such as Pfizer, Alnylam Pharmaceuticals Ionis Pharmaceuticals, AstraZeneca, and BridgeBio Pharma are estimated to account for 35–40% of the global amyloidosis treatment market share.

Established players compete mainly through transthyretin stabilizers, RNA interference therapies, and antisense oligonucleotides. Emerging and regional players in the amyloidosis treatment market ecosystem focus on novel therapeutic approaches, disease-specific therapies, and solutions targeting underlying amyloid protein production.

List of Key and Emerging Players in Amyloidosis Treatment Market